AR133266A1 - Macrociclos para el tratamiento de enfermedades autoinmunitarias - Google Patents

Macrociclos para el tratamiento de enfermedades autoinmunitarias

Info

Publication number
AR133266A1
AR133266A1 ARP240101844A ARP240101844A AR133266A1 AR 133266 A1 AR133266 A1 AR 133266A1 AR P240101844 A ARP240101844 A AR P240101844A AR P240101844 A ARP240101844 A AR P240101844A AR 133266 A1 AR133266 A1 AR 133266A1
Authority
AR
Argentina
Prior art keywords
macrocycles
treatment
autoimmune diseases
compounds
formula
Prior art date
Application number
ARP240101844A
Other languages
English (en)
Inventor
Buyu Kou
Haixia Liu
Hong Shen
Yao Wu
Zhiwei Zhang
Wei Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR133266A1 publication Critical patent/AR133266A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (1), en donde R¹ a R⁶, Q¹ y A¹ a A⁵ son como se describe en la presente, y su sal farmacéuticamente aceptable, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
ARP240101844A 2023-07-19 2024-07-16 Macrociclos para el tratamiento de enfermedades autoinmunitarias AR133266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2023108207 2023-07-19

Publications (1)

Publication Number Publication Date
AR133266A1 true AR133266A1 (es) 2025-09-10

Family

ID=91966078

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101844A AR133266A1 (es) 2023-07-19 2024-07-16 Macrociclos para el tratamiento de enfermedades autoinmunitarias

Country Status (13)

Country Link
EP (1) EP4746963A1 (es)
JP (1) JP2026525329A (es)
KR (1) KR20260040007A (es)
CN (1) CN121568945A (es)
AR (1) AR133266A1 (es)
AU (1) AU2024296084A1 (es)
CL (1) CL2026000081A1 (es)
CO (1) CO2026000531A2 (es)
IL (1) IL324969A (es)
MX (1) MX2026000537A (es)
PE (1) PE20260753A1 (es)
TW (1) TW202510858A (es)
WO (1) WO2025017045A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
KR20210146370A (ko) * 2019-03-28 2021-12-03 루핀 리미티드 Sting 효능제로서의 매크로사이클릭 화합물
DK4004002T3 (da) * 2019-07-22 2024-09-30 Lupin Ltd Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed
IL314136A (en) * 2022-02-02 2024-09-01 Hoffmann La Roche Imidazole macrocycles for the treatment of autoimmune disease

Also Published As

Publication number Publication date
AU2024296084A1 (en) 2025-12-11
KR20260040007A (ko) 2026-03-23
CO2026000531A2 (es) 2026-02-02
CN121568945A (zh) 2026-02-24
IL324969A (en) 2026-01-01
TW202510858A (zh) 2025-03-16
PE20260753A1 (es) 2026-03-31
CL2026000081A1 (es) 2026-04-06
JP2026525329A (ja) 2026-07-29
EP4746963A1 (en) 2026-05-27
WO2025017045A1 (en) 2025-01-23
MX2026000537A (es) 2026-03-02

Similar Documents

Publication Publication Date Title
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
AR132340A1 (es) Compuestos tricíclicos para el tratamiento de cáncer
CO2025010435A2 (es) Compuestos tricíclicos para el tratamiento de cáncer
CO2025001184A2 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
CO2024017733A2 (es) Inhibidores macrocíclicos de kras para el tratamiento de cáncer
AR133199A1 (es) Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CO2024011088A2 (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2026000531A2 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
BR112021017620A2 (pt) Compostos macrocíclicos
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
MX2023015490A (es) Inhibidores de las transglutaminasas.
MX2025002817A (es) Compuestos para el tratamiento del cancer
CL2024001635A1 (es) Compuestos de diazaspiro sustituidos con carbonilo y su uso
CO2025011377A2 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria
CL2024000791A1 (es) Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias